Myasthenia Gravis, Generalized Clinical Trials

10 recruitingLast updated: May 13, 2026

There are 10 actively recruiting myasthenia gravis, generalized clinical trials across 6 countries. Studies span Phase 2, Phase 3, Phase 4. Top locations include Roma, Italy, Boca Raton, Florida, United States, Bydgoszcz, Poland. Updated daily from ClinicalTrials.gov.


Myasthenia Gravis, Generalized Trials at a Glance

10 actively recruiting trials for myasthenia gravis, generalized are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Roma, Boca Raton, and Bydgoszcz. Lead sponsors running myasthenia gravis, generalized studies include Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Brain Inflammation Collaborative, and AstraZeneca.

Browse myasthenia gravis, generalized trials by phase

Treatments under study

About Myasthenia Gravis, Generalized Clinical Trials

Looking for clinical trials for Myasthenia Gravis, Generalized? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myasthenia Gravis, Generalized trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myasthenia Gravis, Generalized clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
Vertex Pharmaceuticals Incorporated30 enrolled6 locationsNCT07501702
Recruiting

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
AstraZeneca50 enrolled14 locationsNCT06909253
Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Traumatic Brain InjuryEhlers-Danlos SyndromePost-Acute COVID-19 Syndrome+41 more
Brain Inflammation Collaborative10,000 enrolled1 locationNCT04806620
Recruiting
Phase 4

Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

Myasthenia Gravis, Generalized
Centre Hospitalier Universitaire de Nice50 enrolled1 locationNCT07072988
Recruiting
Phase 3

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

Myasthenia Gravis, Generalized
Fondazione Policlinico Universitario Agostino Gemelli IRCCS40 enrolled1 locationNCT05868837
Recruiting

Markers of Favorable Response to Complement Inhibitors Therapy

Myasthenia Gravis, Generalized
Fondazione Policlinico Universitario Agostino Gemelli IRCCS50 enrolled1 locationNCT06455709
Recruiting
Phase 2

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
Tang-Du Hospital64 enrolled6 locationsNCT05067348
Recruiting

Markers of Favorable Response to FcRn Inhibitors(INFORM)

Myasthenia Gravis, Generalized
Fondazione Policlinico Universitario Agostino Gemelli IRCCS50 enrolled1 locationNCT06685055
Recruiting

Myasthenia Gravis Foundation of America Global MG Patient Registry

Myasthenia GravisMyasthenia Gravis, GeneralizedMyasthenia+10 more
Myasthenia Gravis Foundation of America3,800 enrolled1 locationNCT06617741
Recruiting

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Myasthenia GravisThymomaNervous System Diseases+9 more
Assiut University30 enrolled1 locationNCT05214612